Listed by the USPTO as PAULUS, ERIN VIRGINIA
Tech Center 1600 • Art Units: 1631 1643
This examiner grants 20% of resolved cases
Paulus, Erin Virginia is assigned to Tech Center 1600 and Art Unit 1631. The profile contains 20 resolved cases, an allowance rate of 20.0%, an interview lift of 94.1%, and a median of 1277 days to allowance. The interview measure is much higher than the allowance rate, making examiner interviews a notable feature of the available record despite the limited sample.
The listed companies are Korea University Research and Business Foundation, Massachusetts Institute of Technology, and BIOTISSUE HOLDINGS INC. The leading firms are SUGHRUE MION, PLLC, OBLON, MCCLELLAND, MAIER & NEUSTADT, L.L.P., and CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC. Practitioners should treat the statistics as directional and pair any interview strategy with careful claim and evidence development.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18394297 | COMPOSITIONS AND METHODS FOR AMELIORATING ANTERODORSAL THALAMUS HYPEREXCITABILITY | Non-Final OA | Massachusetts Institute of Technology |
| 17937975 | ULTRASONIC GENETICALLY ENCODED CALCIUM INDICATORS | Final Rejection | California Institute of Technology |
| 18279034 | STRATEGIES TO DEVELOP GENOME EDITING SPHERICAL NUCLEIC ACIDS (SNAS) | Non-Final OA | NORTHWESTERN UNIVERSITY |
| 18044667 | METHOD FOR QUICKLY AND EFFICIENTLY DIFFERENTIATING FUNCTIONAL GLIAL CELLS | Non-Final OA | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 17774645 | DROPLET DEFORMATION-BASED METHOD OF TRANSFERRING MATERIAL INTO CELLS AND CHIP FOR SAME | Non-Final OA | Korea University Research and Business Foundation |
| 18411891 | MATERIAL AND METHOD FOR PREPARATION OF SMALL, SINGLE-STRANDED DNA CIRCLES | Non-Final OA | Purdue Research Foundation |
| 18033639 | MODIFIED SIGNAL PEPTIDE | Final Rejection | KAO CORPORATION |
| 17876993 | Method of Demineralizing Bone with an Ionic Solution | Final Rejection | Newsouth Innovations Pty Limited |
| 18553295 | Gene Therapy for Retinal Disease | Non-Final OA | OXFORD UNIVERSITY INNOVATION LIMITED |
| 18043818 | SQUALENE HOPENE CYCLASE DERIVATIVES AND USE THEREOF FOR PRODUCING AMBROX | Final Rejection | INTERNATIONAL FLAVORS & FRAGRANCES, INC. |
| 17810982 | PLASMODIUM VIVAX MALE GAMETE FUSION PROTEIN PVHAP2 AND THE PUTATIVE PROLIFERATING-CELL NUCLEOLAR ANTIGEN P120 AS RELAPSE BIOMARKERS | Final Rejection | Seattle Children's Hospital dba Seattle Children's Research Institute |
| 18278915 | METHOD FOR PREPARING BONE-MARROW-DERIVED ENDOTHELIAL PROGENITOR CELLS HAVING INCREASED VASCULOGENESIS BY USING PDGF-BB, AND METHOD FOR PREPARING CELL THERAPEUTIC AGENT FOR TREATING ANANGIOPLASIA-RELATED DISEASES BY USING METHOD | Final Rejection | ELPHIS CELL THERAPEUTICS |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy20.0% of resolved applications examined by Erin Virginia Paulus were allowed (20 resolved cases), compared with 28.4% across Art Unit 1631 over the last five years.
This examiner's interview lift is +94.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Erin Virginia Paulus took 1,277 days on average from filing to allowance.
Erin Virginia Paulus examines applications in Art Unit 1631 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
